Alamar Biosciences Reports 68% Year-Over-Year Revenue Growth in Q3 2026
Alamar Biosciences (ALMR) reported strong third-quarter 2026 financial results, with total revenue reaching $33.5 million, a 68% increase compared to the previous year. This growth was primarily fueled by a 79% surge in consumables revenue and a 50% rise in instrument placements. Notably, biopharmaceutical companies became the company's largest customer segment for the first time, accounting for 49% of total revenue. Despite the top-line strength and an all-time high gross margin of 61.5%, the company reported a net loss of $13.3 million due to increased operating investments in R&D and SG&A. However, management raised its full-year 2026 revenue guidance to a range of $121 million to $123 million, supported by a robust cash position of $231.5 million.
Tickers: $ALMR
Topics: Consumables Demand Gross Margin Guidance Raise Revenue Growth